A multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in
vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process,
and injected in patients with an acute myocardial infarction and a LVEF remaining below 50%
after reperfusion versus standard of care.